AbbVie licenses DISCO Pharmaceuticals' bispecific platform in up to $2.54B solid-tumour deal
What's the deal? AbbVie and DISCO Pharmaceuticals, a German precision-medicine biotech focused on the surfaceome — the set of proteins displayed on cell surfaces — announced a licensing agreement on 19 November 2026 under which AbbVie gains an option to develop novel AND-gated bispecific therapeutics for solid tumours with high unmet medical need. The deal is worth up to $2.54 billion in potential milestones (biobucks); upfront and per-program financial terms were not disclosed.
Why it matters: DISCO's logic-based bispecific platform maps new cell-surface targets to build therapies such as antibody-drug conjugates (drugs that deliver a toxic payload to cancer cells via a targeting antibody) and T-cell engagers (which recruit immune T cells to attack tumours). "AND-gated" designs are engineered to activate only when both of two specific targets are present, which is intended to sharpen tumour selectivity and limit damage to healthy tissue. The deal is DISCO's second major pharma partnership of 2026, following an Amgen licensing agreement in January worth up to $618 million — a validation of the platform's broader applicability across the industry.
Read more: BioSpace, 19 November 2026 · Reuters, 19 November 2026